Synonyms
Background
Fibroblast growth factorāinducible-14 (Fn14) was described in fibroblasts as an immediate-early response gene to growth factors. Fn14 is a member of the TNF receptor superfamily (TNFRSF), also termed TNFRSF12A. The only ligand for Fn14 is the cytokine TWEAK (Wiley and Winkles 2003), and Fn14 is the only signaling receptor for TWEAK. Both have been targeted therapeutically in humans.
Structure
Phylogenetically Fn14 is much conserved and there is a 90% homology between the mouse and the human protein (Wiley and Winkles 2003). The human Fn14 gene is located at chromosomal position 16p13.3, encodes a type I transmembrane protein of 129 aa that is processed into a mature 102-aa protein, and is the smallest member of the TNFRSF (Wiley and Winkles 2003). The extracellular domain (53-aa) contains a cysteine-rich domain typical of TNFRSF members, required for the interaction with TWEAK (He et al. 2009). Conversely, the Tyr176 residue of...
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Brown SA, Richards CM, Hanscom HN, Feng SL, Winkles JA. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem J. 2003;371:395ā403.
Brown SA, Cheng E, Williams MS, Winkles JA. TWEAK-independent Fn14 self-association and NF-ĪŗB activation is mediated by the C-terminal region of the Fn14 cytoplasmic domain. PLoS One. 2013;8:e65248.
Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine. 2007;40:1ā16.
Chen HN, Wang DJ, Ren MY, Wang QL, Sui SJ. TWEAK/Fn14 promotes the proliferation and collagen synthesis of rat cardiac fibroblasts via the NF-ŠŗB pathway. Mol Biol Rep. 2012;39:8231ā41.
Chen S, Liu J, Yang M, Lai W, Ye L, Chen J, Hou X, Ding H, Zhang W, Wu Y, et al. Fn14, a downstream target of the TGF-Ī² signaling pathway, regulates fibroblast activation. PLoS One. 2015;10:e0143802.
Cheng H, Xu M, Liu X, Zou X, Zhan N, Xia Y. TWEAK/Fn14 activation induces keratinocyte proliferation under psoriatic inflammation. Exp Dermatol. 2016;25:32ā7.
Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I, Browning JL. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem. 1997;272:32401ā10.
Culp PA, Choi D, Zhang Y, Yin J, Seto P, Ybarra SE, Su M, Sho M, Steinle R, Wong MH, et al. Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin Cancer Res. 2010;16:497ā508.
Dai L, Gu L, Ding C, Qiu L, Di W. TWEAK promotes ovarian cancer cell metastasis via NF-kappaB pathway activation and VEGF expression. Cancer Lett. 2009;283:159ā67.
Dhruv H, Loftus JC, Narang P, Petit JL, Fameree M, Burton J, Tchegho G, Chow D, Yin H, Al-Abed Y, et al. Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis. J Biol Chem. 2013;288:32261ā76.
Doerner JL, Wen J, Xia Y, Paz KB, Schairer D, Wu L, Chalmers SA, Izmirly P, Michaelson JS, Burkly LC, et al. TWEAK/Fn14 signaling involvement in the pathogenesis of cutaneous disease in the MRL/lpr model of spontaneous lupus. J Invest Dermatol. 2015;135:1986ā95.
Doerner J, Chalmers SA, Friedman A, Putterman C. Fn14 deficiency protects lupus-prone mice from histological lupus erythematosus-like skin inflammation induced by ultraviolet light. Exp Dermatol. 2016;25(12):969ā76.
Dohi T, Kawashima R, Kawamura YI, Otsubo T, Hagiwara T, Amatucci A, Michaelson J, Burkly LC. Pathological activation of canonical nuclear-factor ĪŗB by synergy of tumor necrosis factor Ī± and TNF-like weak inducer of apoptosis in mouse acute colitis. Cytokine. 2014;69:14ā21.
Enwere EK, Lacasse EC, Adam NJ, Korneluk RG. Role of the TWEAK-Fn14-cIAP1-NF-ĪŗB signaling axis in the regulation of myogenesis and muscle homeostasis. Front Immunol. 2014;5:34.
Gurunathan S, Winkles JA, Ghosh S, Hayden MS. Regulation of fibroblast growth factor-inducible 14 (Fn14) expression levels via ligand-independent lysosomal degradation. J Biol Chem. 2014;289:12976ā88.
He F, Dang W, Saito K, Watanabe S, Kobayashi N, GĆ¼ntert P, Kigawa T, Tanaka A, Muto Y, Yokoyama S. Solution structure of the cysteine-rich domain in Fn14, a member of the tumor necrosis factor receptor superfamily. Protein Sci. 2009;18:650ā6.
HĆ©naut L, Sanchez-Nino MD, Aldamiz-EchevarrĆa Castillo G, Sanz AB, Ortiz A. Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification. Expert Opin Ther Targets. 2016a;20:89ā105.
HĆ©naut L, Sanz AB, Martin-Sanchez D, Carrasco S, Villa-Bellosta R, Aldamiz-Echevarria G, Massy ZA, Sanchez-Nino MD, Ortiz A. TWEAK favors phosphate-induced calcification of vascular smooth muscle cells through canonical and non-canonical activation of NFĪŗB. Cell Death Dis. 2016b;7:e2305.
Huang M, Narita S, Tsuchiya N, Ma Z, Numakura K, Obara T, Tsuruta H, Saito M, Inoue T, Horikawa Y, et al. Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome. Carcinogenesis. 2011;32:1589ā96.
Izquierdo MC, Sanz AB, Mezzano S, Blanco J, Carrasco S, Sanchez-NiƱo MD, Benito-MartĆn A, Ruiz-Ortega M, Egido J, Ortiz A. TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation. Kidney Int. 2012;81:1098ā107.
Johnston AJ, Murphy KT, Jenkinson L, Laine D, Emmrich K, Faou P, Weston R, Jayatilleke KM, Schloegel J, Talbo G, et al. Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival. Cell. 2015;162:1365ā78.
Justo P, Sanz AB, Sanchez-NiƱo MD, Winkles JA, Lorz C, Egido J, Ortiz A. Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int. 2006;70:1750ā8.
Kamijo S, Nakajima A, Kamata K, Kurosawa H, Yagita H, Okumura K. Involvement of TWEAK/Fn14 interaction in the synovial inflammation of RA. Rheumatology (Oxford). 2008;47:442ā50.
Karaca G, Swiderska-Syn M, Xie G, Syn WK, KrĆ¼ger L, Machado MV, Garman K, Choi SS, Michelotti GA, Burkly LC, et al. TWEAK/Fn14 signaling is required for liver regeneration after partial hepatectomy in mice. PLoS One. 2014;9:e83987.
Kwon OH, Park SJ, Kang TW, Kim M, Kim JH, Noh SM, Song KS, Yoo HS, Wang Y, Pocalyko D, et al. Elevated fibroblast growth factor-inducible 14 expression promotes gastric cancer growth via nuclear factor-ĪŗB and is associated with poor patient outcome. Cancer Lett. 2012;314:73ā81.
Linkermann A, BrƤsen JH, Darding M, Jin MK, Sanz AB, Heller JO, De Zen F, Weinlich R, Ortiz A, Walczak H, et al. Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2013;110:12024ā9.
Madrigal-Matute J, Fernandez-Laso V, Sastre C, Llamas-Granda P, Egido J, Martin-Ventura JL, Zalba G, Blanco-Colio LM. TWEAK/Fn14 interaction promotes oxidative stress through NADPH oxidase activation in macrophages. Cardiovasc Res. 2015;108:139ā47.
MartĆnez-Aranda A, HernĆ”ndez V, Guney E, MuixĆ L, Foj R, Baixeras N, Cuadras D, Moreno V, Urruticoechea A, Gil M, et al. FN14 and GRP94 expression are prognostic/predictive biomarkers of brain metastasis outcome that open up new therapeutic strategies. Oncotarget. 2015;6:44254ā73.
Meulendijks D, Lassen UN, Siu LL, Huitema AD, Karanikas V, Mau-Sorensen M, Jonker DJ, Hansen AR, Simcox ME, Schostack KJ, et al. Exposure and tumor Fn14 expression as determinants of pharmacodynamics of the anti-TWEAK monoclonal antibody RG7212 in patients with Fn14-positive solid tumors. Clin Cancer Res. 2016;22:858ā67.
Michaelson JS, Burkly LC. Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway. Results Probl Cell Differ. 2009;49:145ā60.
Michaelson JS, Amatucci A, Kelly R, Su L, Garber E, Day ES, Berquist L, Cho S, Li Y, Parr M, et al. Development of an Fn14 agonistic antibody as an anti-tumor agent. MAbs. 2011;3:362ā75.
Michaelson JS, Kelly R, Yang L, Zhang X, Wortham K, Joseph IB. The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models. Cancer Biol Ther. 2012;13:812ā21.
Min HK, Kim SM, Park JS, Byun JK, Lee J, Kwok SK, Park YW, Cho ML, Park SH. Fn14-Fc suppresses germinal center formation and pathogenic B cells in a lupus mouse model via inhibition of the TWEAK/Fn14 pathway. J Transl Med. 2016;14:98.
Mittal A, Bhatnagar S, Kumar A, Lach-Trifilieff E, Wauters S, Li H, Makonchuk DY, Glass DJ. The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice. J Cell Biol. 2010;188:833ā49.
Moreno JA, Izquierdo MC, Sanchez-NiƱo MD, SuĆ”rez-Alvarez B, Lopez-Larrea C, Jakubowski A, Blanco J, Ramirez R, Selgas R, Ruiz-Ortega M, et al. The inflammatory cytokines TWEAK and TNFĪ± reduce renal klotho expression through NFĪŗB. J Am Soc Nephrol. 2011;22:1315ā25.
Moreno JA, Sastre C, Madrigal-Matute J, MuƱoz-GarcĆa B, Ortega L, Burkly LC, Egido J, MartĆn-Ventura JL, Blanco-Colio LM. HMGB1 expression and secretion are increased via TWEAK-Fn14 interaction in atherosclerotic plaques and cultured monocytes. Arterioscler Thromb Vasc Biol. 2013;33:612ā20.
MuƱoz-GarcĆa B, Moreno JA, LĆ³pez-Franco O, Sanz AB, MartĆn-Ventura JL, Blanco J, Jakubowski A, Burkly LC, Ortiz A, Egido J, et al. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol. 2009;29:2061ā8.
Novoyatleva T, Diehl F, van Amerongen MJ, Patra C, Ferrazzi F, Bellazzi R, Engel FB. TWEAK is a positive regulator of cardiomyocyte proliferation. Cardiovasc Res. 2010;85:681ā90.
Novoyatleva T, Schymura Y, Janssen W, Strobl F, Swiercz JM, Patra C, Posern G, Wietelmann A, Zheng TS, Schermuly RT, et al. Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction. Basic Res Cardiol. 2013;108:325.
Novoyatleva T, Sajjad A, Pogoryelov D, Patra C, Schermuly RT, Engel FB. FGF1-mediated cardiomyocyte cell cycle reentry depends on the interaction of FGFR-1 and Fn14. FASEB J. 2014;28:2492ā503.
Ortiz A, Sanz AB, MuƱoz GarcĆa B, Moreno JA, SĆ”nchez NiƱo MD, MartĆn-Ventura JL, Egido J, Blanco-Colio LM. Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev. 2009;20:251ā8.
Ortiz A, Husi H, Gonzalez-Lafuente L, ValiƱo-Rivas L, Fresno M, Sanz AB, Mullen W, Albalat A, Mezzano S, Vlahou T, et al. Mitogen-activated protein kinase 14 promotes AKI. J Am Soc Nephrol. 2017;28(3): 823ā36.
Purcell JW, Kim HK, Tanlimco SG, Doan M, Fox M, Lambert P, Chao DT, Sho M, Wilson KE, Starling GC, et al. Nuclear factor ĪŗB is required for tumor growth inhibition mediated by enavatuzumab (PDL192), a humanized monoclonal antibody to TweakR. Front Immunol. 2014;4:505.
Rayego-Mateos S, Morgado-Pascual JL, Sanz AB, Ramos AM, Eguchi S, Batlle D, Pato J, Keri G, Egido J, Ortiz A, et al. TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation. J Pathol. 2013;231:480ā94.
Ruiz-Andres O, Suarez-Alvarez B, SĆ”nchez-Ramos C, Monsalve M, Sanchez-NiƱo MD, Ruiz-Ortega M, Egido J, Ortiz A, Sanz AB. The inflammatory cytokine TWEAK decreases PGC-1Ī± expression and mitochondrial function in acute kidney injury. Kidney Int. 2016;89(2):399ā410.
Sanchez-NiƱo MD, Poveda J, Sanz AB, Mezzano S, Carrasco S, Fernandez-Fernandez B, Burkly LC, Nair V, Kretzler M, Hodgin JB, et al. Fn14 in podocytes and proteinuric kidney disease. Biochim Biophys Acta. 2013;1832:2232ā43.
Sanz AB, Sanchez-NiƱo MD, Izquierdo MC, Jakubowski A, Justo P, Blanco-Colio LM, Ruiz-Ortega M, Egido J, Ortiz A. Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia. J Cell Mol Med. 2009;13:3329ā42.
Sanz AB, Sanchez-NiƱo MD, Carrasco S, Manzarbeitia F, Ruiz-Andres O, Selgas R, Ruiz-Ortega M, Gonzalez-Enguita C, Egido J, Ortiz A. Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells. PLoS One. 2012;7:e47440.
Sanz AB, Aroeira LS, Bellon T, del Peso G, Jimenez-Heffernan J, Santamaria B, Sanchez-NiƱo MD, Blanco-Colio LM, Lopez-Cabrera M, Ruiz-Ortega M, et al. TWEAK promotes peritoneal inflammation. PLoS One. 2014a;9:e90399.
Sanz AB, Izquierdo MC, Sanchez-NiƱo MD, Ucero AC, Egido J, Ruiz-Ortega M, Ramos AM, Putterman C, Ortiz A. TWEAK and the progression of renal disease: clinical translation. Nephrol Dial Transplant. 2014b;29(Suppl 1):i54ā62.
Sanz AB, Ruiz-Andres O, Sanchez-NiƱo MD, Ruiz-Ortega M, Ramos AM, Ortiz A. Out of the TWEAKlight: elucidating the role of Fn14 and TWEAK in acute kidney injury. Semin Nephrol. 2016;36:189ā98.
Sharif MN, Campanholle G, Nagiec EE, Wang J, Syed J, OāNeil SP, Zhan Y, Brenneman K, Homer B, Neubert H, et al. Soluble Fn14 is detected and elevated in mouse and human kidney disease. PLoS One. 2016;11:e0155368.
Tajrishi MM, Sato S, Shin J, Zheng TS, Burkly LC, Kumar A. The TWEAK-Fn14 dyad is involved in age-associated pathological changes in skeletal muscle. Biochem Biophys Res Commun. 2014a;446:1219ā24.
Tajrishi MM, Shin J, Hetman M, Kumar A. DNA methyltransferase 3a and mitogen-activated protein kinase signaling regulate the expression of fibroblast growth factor-inducible 14 (Fn14) during denervation-induced skeletal muscle atrophy. J Biol Chem. 2014b;289:19985ā99.
Tajrishi MM, Zheng TS, Burkly LC, Kumar A. The TWEAK-Fn14 pathway: a potent regulator of skeletal muscle biology in health and disease. Cytokine Growth Factor Rev. 2014c;25:215ā25.
TarĆn C, FernĆ”ndez-Laso V, Sastre C, Madrigal-Matute J, GĆ³mez M, Zaragoza C, Egido J, Burkly LC, MartĆn-Ventura JL, Blanco-Colio LM. Tumor necrosis factor-like weak inducer of apoptosis or Fn14 deficiency reduce elastase perfusion-induced aortic abdominal aneurysm in mice. J Am Heart Assoc. 2014;3(11):pii e000723.
Tirnitz-Parker JE, Viebahn CS, Jakubowski A, Klopcic BR, Olynyk JK, Yeoh GC, Knight B. Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. Hepatology. 2010;52:291ā302.
Ucero AC, Benito-Martin A, Fuentes-Calvo I, Santamaria B, Blanco J, Lopez-Novoa JM, Ruiz-Ortega M, Egido J, Burkly LC, Martinez-Salgado C, et al. TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast. Biochim Biophys Acta. 2013a;1832(10):1744ā55.
Ucero AC, Berzal S, OcaƱa-Salceda C, Sancho M, OrzƔez M, Messeguer A, Ruiz-Ortega M, Egido J, Vicent MJ, Ortiz A, et al. A polymeric nanomedicine diminishes inflammatory events in renal tubular cells. PLoS One. 2013b;8:e51992.
ValiƱo-Rivas L, Gonzalez-Lafuente L, Sanz AB, Ruiz-Ortega M, Ortiz A, Sanchez-NiƱo MD. Non-canonical NFĪŗB activation promotes chemokine expression in podocytes. Sci Rep. 2016;6:28857.
van Kuijk AW, Wijbrandts CA, Vinkenoog M, Zheng TS, Reedquist KA, Tak PP. TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade. Ann Rheum Dis. 2010;69:301ā4.
Wang S, Jiang W, Chen X, Zhang C, Li H, Hou W, Liu Z, McNutt MA, Lu F, Li G. Alpha-fetoprotein acts as a novel signal molecule and mediates transcription of Fn14 in human hepatocellular carcinoma. J Hepatol. 2012;57:322ā9.
Wen J, Xia Y, Stock A, Michaelson JS, Burkly LC, Gulinello M, Putterman C. Neuropsychiatric disease in murine lupus is dependent on the TWEAK/Fn14 pathway. J Autoimmun. 2013;43:44ā54.
Wen J, Doerner J, Weidenheim K, Xia Y, Stock A, Michaelson JS, Baruch K, Deczkowska A, Gulinello M, Schwartz M, et al. TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice. J Autoimmun. 2015;60:40ā50.
Whitsett TG, Cheng E, Inge L, Asrani K, Jameson NM, Hostetter G, Weiss GJ, Kingsley CB, Loftus JC, Bremner R, et al. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol. 2012;181:111ā20.
Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev. 2003;14:241ā9.
Wilhelm A, Shepherd EL, Amatucci A, Munir M, Reynolds G, Humphreys E, Resheq Y, Adams DH, HĆ¼bscher S, Burkly LC, et al. Interaction of TWEAK with Fn14 leads to the progression of fibrotic liver disease by directly modulating hepatic stellate cell proliferation. J Pathol. 2016;239:109ā21.
Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov. 2008;7:411ā25.
Wisniacki N, Amaravadi L, Galluppi GR, Zheng TS, Zhang R, Kong J, Burkly LC. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis. Clin Ther. 2013;35:1137ā49.
Wu F, Guo L, Jakubowski A, Su L, Li WC, Bonner-Weir S, Burkly LC. TNF-like weak inducer of apoptosis (TWEAK) promotes beta cell neogenesis from pancreatic ductal epithelium in adult mice. PLoS One. 2013;8:e72132.
Xia Y, Herlitz LC, Gindea S, Wen J, Pawar RD, Misharin A, Perlman H, Wu L, Wu P, Michaelson JS, et al. Deficiency of fibroblast growth factor-inducible 14 (Fn14) preserves the filtration barrier and ameliorates lupus nephritis. J Am Soc Nephrol. 2014;26(5):1053ā70.
Yadava RS, Foff EP, Yu Q, Gladman JT, Kim YK, Bhatt KS, Thornton CA, Zheng TS, Mahadevan MS. TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy. Hum Mol Genet. 2015;24:2035ā48.
Yin X, Luistro L, Zhong H, Smith M, Nevins T, Schostack K, Hilton H, Lin TA, Truitt T, Biondi D, et al. RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response. Clin Cancer Res. 2013;19:5686ā98.
Zhao Z, Burkly LC, Campbell S, Schwartz N, Molano A, Choudhury A, Eisenberg RA, Michaelson JS, Putterman C. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol. 2007;179:7949ā58.
Zhou H, Ekmekcioglu S, Marks JW, Mohamedali KA, Asrani K, Phillips KK, Brown SA, Cheng E, Weiss MB, Hittelman WN, et al. The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. J Invest Dermatol. 2013a;133:1052ā62.
Zhou H, Hittelman WN, Yagita H, Cheung LH, Martin SS, Winkles JA, Rosenblum MG. Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors. Cancer Res. 2013b;73:4439ā50.
Zhou H, Mohamedali KA, Gonzalez-Angulo AM, Cao Y, Migliorini M, Cheung LH, LoBello J, Lei X, Qi Y, Hittelman WN, et al. Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC. Mol Cancer Ther. 2014;13:2688ā705.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2018 Springer International Publishing AG
About this entry
Cite this entry
Martin-Sanchez, D. et al. (2018). Fn14. In: Choi, S. (eds) Encyclopedia of Signaling Molecules. Springer, Cham. https://doi.org/10.1007/978-3-319-67199-4_594
Download citation
DOI: https://doi.org/10.1007/978-3-319-67199-4_594
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-67198-7
Online ISBN: 978-3-319-67199-4
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences